Abstract
Progress in molecular biology over the past several years has advanced our understanding of the pathology of leukemia. Researchers have identified a long list of the cytogenetic and molecular abnormalities associated with these diseases. However, a significant unmet need remains for medical therapies for leukemia, especially in older patients.
Copyright 2002, Elsevier Science (USA). All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Alkyl and Aryl Transferases / antagonists & inhibitors*
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use*
-
Enzyme Inhibitors / administration & dosage
-
Enzyme Inhibitors / therapeutic use
-
Farnesyltranstransferase
-
Hematologic Neoplasms / drug therapy*
-
Hematologic Neoplasms / genetics
-
Humans
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
-
Myelodysplastic Syndromes / drug therapy
-
Myelodysplastic Syndromes / genetics
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Alkyl and Aryl Transferases
-
Farnesyltranstransferase